NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Apogee Therapeutics, Inc. (APGE) Stock Analysis

Apogee Therapeutics, Inc. (APGE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APGE

$135.07

$0.00 (0.00%)

Sep 3, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APGE with… →

APGE Key Statistics

As of Sep 3, 2026
Trading
Open
$135.07
Previous Close
$135.07
52-Week Range
35.39–135.09
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.33
Valuation
Market Cap
$10.22B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.34
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$255.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.20M
1-Year Return
+253.96%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
2.79M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APGE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+78.95%
2025+66.62%
2024+62.13%
2023 (partial year)+31.61%

As of September 3, 2026.

APGE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$255.84M—
2024$0.00−$182.15M—
2023$0.00−$83.99M—
2022$0.00−$39.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$285.60M−$255.84M—
2024$0.00—−$216.87M−$182.15M—
2023$0.00—−$93.00M−$83.99M—
2022$0.00—−$30.73M−$39.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APGE Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPGEBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Apogee Therapeutics, Inc. (APGE) at $10.22B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 261 employees.

The most recent close on file for APGE is $135.07, dated September 3, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $35.39 to $135.09. The latest close sits 281.66% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $255.84M. Profit margin runs at 0%. Trailing earnings per share are −4.34.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +253.96%. Measured over 3 years, that is +76.16% a year compounded. The reported beta is 0.33. Annualized volatility over the trailing 3 years is 71.12%.

Growth & Income

No dividend is on file for APGE.

Across the complete calendar years on file, 2025 returned +66.62% and 2024 returned +62.13%. So far in 2026 the price is +78.95%.

Peer Comparison

Apogee Therapeutics, Inc. (APGE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apogee Therapeutics, Inc. APGE $10.22B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Apogee Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 3, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.

Visit website →